Subcutaneous anti-amyloid formulations move toward filing
Subcutaneous lecanemab data has been submitted to regulators; subcutaneous donanemab is in late development. Both reframe the access question.
A weekly self-administered injection at home is fundamentally different from a biweekly infusion at a center.
Both leading anti-amyloid antibodies are being developed in subcutaneous formulations, with the explicit goal of decompressing the infusion-chair bottleneck that defines current rollout.
The clinical equivalence question — whether subcutaneous delivery achieves comparable amyloid clearance to IV — is the central scientific bar. Pharmacokinetic and biomarker data so far are supportive, with regulatory submissions either filed or imminent.
The implications, assuming approval:
- Care setting shifts. Self-administered injection moves treatment from infusion centers to home or primary care.
- MRI surveillance does not go away. The ARIA monitoring schedule remains a constraint regardless of how the drug is delivered.
- Adherence becomes a new variable. Self-administered chronic biologics in other therapeutic areas show meaningful adherence gaps, particularly in cognitive impairment populations.
Subcutaneous delivery is not a small-print line item. It is the most consequential near-term change to the rollout shape.
Key sources
- Eisai/Biogen subcutaneous lecanemab regulatory submissions and disclosures
- Eli Lilly subcutaneous donanemab development updates
- FDA prescribing information — Leqembi and Kisunla (current IV labels)